Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Amgen’s next-generation cholesterol drug has ... We look forward to our outcomes study, FOURIER, and will continue to work with payers to improve access for patients who need additional LDL ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

"Amgen's decision to expand its foot here is a perfect example of how our nations can work together to harness innovation, talent and technology." Trump intends to impose "25% or higher" levies on ...

Amgen today is the biggest biotechnology company ... Members of staff “drove beat up cars and rode their bikes to work” and took part in a company culture that would work late, but also ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

Amgen reported fourth-quarter 2024 adjusted earnings ... insurance reverification and increased co-pay expenses as U.S. patients work through deductibles. Tezspire (tezepelumab) recorded sales ...